Vaccinex Inc
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheime… Read more
Vaccinex Inc (VCNX) - Net Assets
Latest net assets as of September 2024: $-1.32 Million USD
Based on the latest financial reports, Vaccinex Inc (VCNX) has net assets worth $-1.32 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.85 Million) and total liabilities ($6.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.32 Million |
| % of Total Assets | -27.21% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 48.55 |
Vaccinex Inc - Net Assets Trend (2016–2023)
This chart illustrates how Vaccinex Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vaccinex Inc (2016–2023)
The table below shows the annual net assets of Vaccinex Inc from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-2.31 Million | -144.50% |
| 2022-12-31 | $5.19 Million | -29.94% |
| 2021-12-31 | $7.41 Million | +383.77% |
| 2020-12-31 | $-2.61 Million | -14.86% |
| 2019-12-31 | $-2.27 Million | -114.82% |
| 2018-12-31 | $15.34 Million | +965.80% |
| 2017-12-31 | $-1.77 Million | +46.77% |
| 2016-12-31 | $-3.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vaccinex Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17140000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $337.62 Million | % |
| Total Equity | $-2.31 Million | 100.00% |
Vaccinex Inc Competitors by Market Cap
The table below lists competitors of Vaccinex Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TORCHMARK CORP - Dusseldorf Stock Exchang
DU:TMJ
|
$1.12 Million |
|
Turbogen Chp
TA:TURB
|
$1.12 Million |
|
Powerdyne International Inc
PINK:PWDY
|
$1.12 Million |
|
Ionic Rare Earths Limited
PINK:IXRRF
|
$1.13 Million |
|
EPAM SYSTEMS (E3M.SG)
STU:E3M
|
$1.12 Million |
|
Daewoong Pharmaceutical Co. Ltd.
KQ:069620
|
$1.12 Million |
|
Pearl Polymers Limited
NSE:PEARLPOLY
|
$1.12 Million |
|
Bentre Aquaproduct Import and Export JSC
VN:ABT
|
$1.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vaccinex Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 5,193,000 to -2,311,000, a change of -7,504,000 (-144.5%).
- Net loss of 20,251,000 reduced equity.
- New share issuances of 11,323,000 increased equity.
- Other factors increased equity by 1,424,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.25 Million | -876.29% |
| Share Issuances | $11.32 Million | +489.96% |
| Other Changes | $1.42 Million | +61.62% |
| Total Change | $- | -144.50% |
Book Value vs Market Value Analysis
This analysis compares Vaccinex Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-125.79 | $0.98 | x |
| 2017-12-31 | $-506.10 | $0.98 | x |
| 2018-12-31 | $-346.59 | $0.98 | x |
| 2019-12-31 | $-427.75 | $0.98 | x |
| 2020-12-31 | $-297.06 | $0.98 | x |
| 2021-12-31 | $53.95 | $0.98 | x |
| 2022-12-31 | $25.70 | $0.98 | x |
| 2023-12-31 | $-4.98 | $0.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vaccinex Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3552.81%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-86.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -4412.34% | 0.11x | 0.00x | $-13.61 Million |
| 2017 | 0.00% | -20802.22% | 0.02x | 0.00x | $-17.35 Million |
| 2018 | 0.00% | -4077.07% | 0.03x | 0.00x | $-28.66 Million |
| 2019 | 0.00% | -6121.41% | 0.11x | 0.00x | $-29.39 Million |
| 2020 | 0.00% | -58618.00% | 0.00x | 0.00x | $-26.65 Million |
| 2021 | -313.44% | -2581.33% | 0.09x | 1.33x | $-23.97 Million |
| 2022 | -379.78% | -19722.00% | 0.01x | 1.54x | $-20.24 Million |
| 2023 | 0.00% | -3552.81% | 0.16x | 0.00x | $-20.02 Million |
Industry Comparison
This section compares Vaccinex Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vaccinex Inc (VCNX) | $-1.32 Million | 0.00% | N/A | $1.12 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |